NXL Stock Overview
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nexalin Technology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.39 |
| 52 Week High | US$3.40 |
| 52 Week Low | US$0.25 |
| Beta | 0 |
| 1 Month Change | 123.39% |
| 3 Month Change | 295.04% |
| 1 Year Change | 66.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| NXL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.8% | 1.6% | 1.0% |
| 1Y | 66.8% | -1.4% | 21.9% |
Price Volatility
| NXL volatility | |
|---|---|
| NXL Average Weekly Movement | 37.6% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NXL's share price has been volatile over the past 3 months.
Volatility Over Time: NXL's weekly volatility has increased from 25% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Mark White | www.nexalin.com |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company’s Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders.
Nexalin Technology, Inc. Fundamentals Summary
| NXL fundamental statistics | |
|---|---|
| Market cap | US$10.30m |
| Earnings (TTM) | -US$4.65m |
| Revenue (TTM) | US$110.75k |
93.0x
P/S Ratio-2.2x
P/E RatioIs NXL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXL income statement (TTM) | |
|---|---|
| Revenue | US$110.75k |
| Cost of Revenue | US$25.69k |
| Gross Profit | US$85.06k |
| Other Expenses | US$4.73m |
| Earnings | -US$4.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 76.81% |
| Net Profit Margin | -4,197.56% |
| Debt/Equity Ratio | 0% |
How did NXL perform over the long term?
See historical performance and comparison